ZIG
ALXN

Zurich Insurance Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Zurich Insurance Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-43,656
Closed -$4.28M – 504
2019
Q3 		$4.28M Buy
43,656
+1,442
+3% +$163K 0.08% 267
2019
Q2 		$5.53M Buy
+42,214
New +$5.44M 0.11% 227
2018
Q2 		– Sell
-49,299
Closed -$5.5M – 558
2018
Q1 		$5.5M Buy
49,299
+15,229
+45% +$1.82M 0.13% 219
2017
Q4 		$4.07M Buy
34,070
+4,181
+14% +$509K 0.1% 258
2017
Q3 		$4.19M Sell
29,889
-1,390
-4% -$189K 0.11% 212
2017
Q2 		$3.81M Sell
31,279
-619
-2% -$72K 0.11% 237
2017
Q1 		$3.87M Buy
31,898
+2,577
+9% +$332K 0.11% 230
2016
Q4 		$3.59M Buy
29,321
+189
+0.6% +$23.1K 0.11% 227
2016
Q3 		$3.57M Buy
29,132
+6,196
+27% +$798K 0.12% 207
2016
Q2 		$2.68M Sell
22,936
-11,644
-34% -$1.65M 0.09% 235
2016
Q1 		$4.81M Buy
34,580
+12,298
+55% +$1.81M 0.17% 162
2015
Q4 		$4.25M Buy
+22,282
New +$3.89M 0.15% 167

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Zurich Insurance Group's ALXN Position: Q4 2019 in Review

Zurich Insurance Group sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 43,656 shares — an estimated $4.28M sold.

Zurich Insurance Group first reported a position in ALXN in Q4 2015 and held it in 12 quarters. The position peaked at $5.53M in Q2 2019. 669 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Zurich Insurance Group reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Zurich Insurance Group sold 43,656 Alexion Pharmaceuticals shares in Q4 2019, an estimated $4.28M.
  • Zurich Insurance Group first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 12 quarters.
  • Zurich Insurance Group's Alexion Pharmaceuticals position peaked at $5.53M in Q2 2019.
  • 669 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Zurich Insurance Group's 13F filing for Q4 2019, filed 14 Feb 2020.